logo
logo
TNGX stock ticker logo

Tango Therapeutics, Inc.

NASDAQ•TNGX
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-09-03
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Contact Information
201 Brookline Avenue, Suite 901, Boston, MA, 02215, United States
857-320-4900
www.tangotx.com
Market Cap
$1.99B
P/E (TTM)
-19.6
17.5
Dividend Yield
--
52W High
$17.63
52W Low
$1.03
52W Range
97%
Rank51Top 71.3%
3.0
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.30+0.00%
4-Quarter Trend

FCF

-$29.94M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Collaboration Revenue Increased Total revenue reached $62.4M in 2025, up $20.3M from 2024, driven by Gilead collaboration recognition.
Net Loss Significantly Reduced Net loss narrowed to $101.6M in 2025, down $28.7M compared to $130.3M loss reported in 2024.
Cash Position Supports Operations Cash, equivalents, and restricted cash totaled $114.8M as of 12/31/2025; existing funds support operations into 2028.
Vopimetostat Shows Pancreatic Activity 2L pancreatic cancer mPFS hit 7.2 months with 25% ORR, supporting planned 2026 pivotal trial initiation.

Risk Factors

Substantial Additional Funding Needed Unable to raise capital when needed forces delays or elimination of product development programs or commercialization efforts.
Clinical Trials May Fail Never successfully completed clinical trials; preclinical results are not predictive; failure halts development and approval prospects.
Reliance on Sole API Supplier Sole source API supplier (WuXi AppTec affiliate) faces potential legislative restrictions, significantly harming business operations if lost.
Intense Oncology Competition Facing direct competition in MTA-cooperative PRMT5 inhibitors from BMS, Amgen, and AstraZeneca programs currently in trials.

Outlook

Plan 2L Pivotal Trial Initiation Anticipate initiating a 2L pivotal trial for vopimetostat in second-line MTAP-deleted pancreatic cancer population in 2026.
Expect RAS Combination Efficacy Update Anticipate providing safety and efficacy update in 2026 for vopimetostat combined with RAS(ON) inhibitors from Revolution Medicines.
Advance Next Generation Targets Strategy includes developing next generation precision oncology targets to continue growing pipeline assets efficiently.
Provide Key Program Updates Expect safety and efficacy updates in 2026 for TNG456 (GBM focus) and TNG260 (NSCLC cohort expansion).

Peer Comparison

Revenue (TTM)

ANAB stock ticker logoANAB
$234.60M
+157.0%
XNCR stock ticker logoXNCR
$125.58M
+4.0%
URGN stock ticker logoURGN
$85.57M
-5.3%

Gross Margin (Latest Quarter)

ANAB stock ticker logoANAB
199.8%
+99.5pp
KURA stock ticker logoKURA
97.3%
+0.0pp
RLAY stock ticker logoRLAY
91.4%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TNGX$1.99B-19.6-50.3%8.4%
RLAY$1.89B-6.5-43.2%5.2%
ANAB$1.83B-134.01813.8%79.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 30, 2026
|
EPS:-$0.32
|
Revenue:$500.40K
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data